{"denoms":[{"counts":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"50"}],"units":"Participants"}],"groups":[{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 1 contains patients treated at Dose Level 0 (1 x 10\\^5 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 8.51 x 10\\^4 - 2.80 x 10\\^5 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"BG000","title":"Dose Level 0 of CD20 CAR T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 2 contains patients treated at Dose Level 1 (3.3 x 10\\^5 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 2.81 x 10\\^5 - 8.50 x 10\\^5 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"BG001","title":"Dose Level 1 of CD20 CAR T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 3 contains patients treated at Dose Level 2 (1 x 10\\^6 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 8.51 x 10\\^5 - 2.80 x 10\\^6 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"BG002","title":"Dose Level 2 of CD20 CAR T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 4 contains patients treated at Dose Level 3 (3.3 x 10\\^6 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 2.81 x 10\\^6 - 8.50 x 10\\^6 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"BG003","title":"Dose Level 3 of CD20 CAR-T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 5 contains patients treated at Dose Level 4 (1 x 10\\^7 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: \\> 8.5 x 10\\^6 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"BG004","title":"Dose Level 4 of CD20 CAR-T Cells"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0","value":"43"},{"groupId":"BG001","spread":"9","value":"61"},{"groupId":"BG002","spread":"8","value":"61"},{"groupId":"BG003","spread":"9","value":"59"},{"groupId":"BG004","spread":"8","value":"67"},{"groupId":"BG005","spread":"9","value":"64"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"13"},{"groupId":"BG005","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"31"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"28"},{"groupId":"BG005","value":"46"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"31"},{"groupId":"BG005","value":"50"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Patients enrolled and treated on study."}